中国心理卫生杂志2018，Vol.32Issue(2)：125-129,5.DOI:10.3969/j.issn.1000-6729.2018.02.007
AKT1基因多态性与利培酮治疗精神分裂症8周疗效的关联研究
Association of AKT1 gene polymorphisms with therapeutic effects of 8-week treatment with risperidone
李小钧 1卢天兰 1岳伟华 1张岱1
作者信息
- 1. 北京大学第六医院,北京大学精神卫生研究所,卫生部精神卫生学重点实验室(北京大学),国家精神心理疾病临床医学研究中心(北大六院),北京100191
- 折叠
摘要
Abstract
Objective:To investigate the association of AKT1 gene polymorphism with risperidone in the treatment of first-episode and untreated schizophrenia for 8 weeks.Methods:A total of 150 patients with Chinese schizophrenia who met DSM-Ⅳ,including 128 cases of risperidone (treatment dose 4-6 mg/d) for 8 weeks were treated with risperidone (treatment dose 4-6 mg/d).The Positive and Negative Symptom Scale (PANSS) reduction rate was used to evaluate the curative effect of drugs after 8 weeks.Using DNA sequencing,four single nucleotide polymorphisms (SNP) loci (rs1130214,rs10149779,rs1130233,rs2494732) genotype were detected in 128 Han patients with schizophrenia,and quantitative trait locus analysis (QTL) was used to explore the association between AKT1 gene polymorphisms and the efficacy of risperidone in the treatment of schizophrenia.Results:AKT1 gene rs1130233 (G ＞ A) and rs2494732(C ＞ T) were significantly associated with the increase in PANSS after 8-week risperidone treatment of schizophrenia (P ＜ 0.05).After repeated testing Bonferroni correction was still statistically significant.The correlation between rs1130214and rs10149779 in this sample was not statistically significant (P ＞0.05).Conclusion:This study suggests that polymorphisms of the AKT1 gene may be associated with the efficacy of risperidone in the treatment of schizophrenia in the Chinese Han population and is expected to provide a basis for the prediction of individual drug efficacy.关键词
精神分裂症/AKT1基因/多态性/利培酮/疗效Key words
schizophrenia/AKT1/polymorphisms/risperidone/therapeutic effects分类
医药卫生引用本文复制引用
李小钧,卢天兰,岳伟华,张岱..AKT1基因多态性与利培酮治疗精神分裂症8周疗效的关联研究[J].中国心理卫生杂志,2018,32(2):125-129,5.
